Augmentation of Dopaminergic Agents for Major Depressive Disorder

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: We read with great interest the randomized, double-blind, placebo-controlled clinical trial (RCT) entitled “Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Trial” (osmotic-release oral system methylphenidate [OROS MPH] N = 73, placebo N = 72; mean dose of OROS MPH = 36.4 mg/day), which followed our earlier 4-week RCT (OROS MPH N = 30, placebo N = 30; mean dose of OROS MPH = 34.2 mg/day). In their article, Ravindran et al. referenced our study only in the form of an abstract that was presented in a scientific meeting, without providing any detailed comparisons between the 2 studies. We therefore will briefly introduce our study results using a meta-analytic approach to extract findings from the 2 studies in order to achieve better sample power. We also provide meta-analytic findings from 4 RCTs of modafinil augmentation for unipolar and bipolar depression.

J Clin Psychiatry 2009;70(3):432-433